---
title: "Arcadia Biosciences | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 901 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280682396.md"
datetime: "2026-03-26T20:11:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280682396.md)
  - [en](https://longbridge.com/en/news/280682396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280682396.md)
---

# Arcadia Biosciences | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 901 K

Revenue: As of FY2025 Q4, the actual value is USD 901 K, missing the estimate of USD 1.4 M.

EPS: As of FY2025 Q4, the actual value is USD -0.97, missing the estimate of USD -0.66.

#### Consolidated Balance Sheet Highlights (In thousands)

-   Total assets for Arcadia Biosciences, Inc. were $6,546 as of December 31, 2025, a decrease from $13,517 as of December 31, 2024.
-   Total current assets decreased to $6,356 as of December 31, 2025, from $9,242 as of December 31, 2024.
-   Cash and cash equivalents significantly decreased to $259 as of December 31, 2025, from $4,242 as of December 31, 2024.
-   Total liabilities decreased to $2,406 as of December 31, 2025, from $7,294 as of December 31, 2024.
-   Total stockholders’ equity was $4,140 as of December 31, 2025, down from $6,223 as of December 31, 2024.
-   The accumulated deficit increased to -$281,217 as of December 31, 2025, from -$278,878 as of December 31, 2024.

#### Consolidated Statements of Operations Highlights (In thousands)

-   Total revenues for the year ended December 31, 2025, were $4,858, a slight decrease from $5,045 for the year ended December 31, 2024.
-   Product revenue was $4,858 in 2025, compared to $5,012 in 2024.
-   Cost of revenues increased to $3,098 in 2025 from $2,963 in 2024.
-   Gross margin was $1,760 in 2025, down from $2,082 in 2024.
-   Research and development expenses decreased to $9 in 2025 from $53 in 2024.
-   Selling, general and administrative expenses decreased to $7,001 in 2025 from $9,641 in 2024.
-   Total operating expenses were $7,358 in 2025, a decrease from $8,693 in 2024.
-   The operating loss was -$2,500 in 2025, an improvement from an operating loss of -$3,648 in 2024.
-   Operating margin was -51.46% in 2025, an improvement from -72.31% in 2024.
-   Net loss from continuing operations was -$2,339 in 2025, an improvement from -$4,317 in 2024.
-   The net loss attributable to common stockholders was -$2,339 in 2025, significantly better than -$7,038 in 2024.
-   Comprehensive loss for 2025 was -$2,339, compared to -$7,139 in 2024.

#### Consolidated Statements of Cash Flows Highlights (In thousands)

-   Net cash used in operating activities decreased to -$4,739 for the year ended December 31, 2025, from -$9,627 for the year ended December 31, 2024.
-   Net cash provided by investing activities was $750 in 2025, a decrease from $7,342 in 2024.
-   Net cash provided by financing activities was $6 in 2025, slightly down from $9 in 2024.
-   Free cash flow was -$4,739 in 2025, compared to -$9,643 in 2024.
-   The net decrease in cash and cash equivalents was -$3,983 in 2025, compared to -$2,276 in 2024.

### Related Stocks

- [RKDA.US](https://longbridge.com/en/quote/RKDA.US.md)

## Related News & Research

- [Abundia Global Impact amends 8-K to disclose 2025 equity plan share increase](https://longbridge.com/en/news/287111321.md)
- [West Pharma amends 8-K on material cyberattack disclosure](https://longbridge.com/en/news/287111623.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)
- [A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data](https://longbridge.com/en/news/286722721.md)
- [DNB Asset Management AS Has $5.68 Million Holdings in Natera, Inc. $NTRA](https://longbridge.com/en/news/286872394.md)